Chemoprevention - History and general principles

Best Practice and Research: Clinical Gastroenterology

Volumn 25, Issue 4-5, 2011, Pages 445-459

  Wu, Xiangwei ^a   Patterson, Sherri ^a   Hawk, Ernest ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Cancer; Chemoprevention

Indexed keywords

ALPHA TOCOPHEROL; AMINOLEVULINIC ACID; BCG VACCINE; BETA CAROTENE; CALCIUM CARBONATE; CELECOXIB; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DUTASTERIDE; FINASTERIDE; FLUOROURACIL; NONSTEROID ANTIINFLAMMATORY AGENT; NORDIHYDROGUAIARETIC ACID; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SELENIUM; TAMOXIFEN; VALRUBICIN; WART VIRUS VACCINE;

ACTINIC KERATOSIS; BLADDER CANCER; BREAST CANCER; CANCER PREVENTION; CARCINOGENESIS; CELL DIFFERENTIATION; CHEMOPROPHYLAXIS; COLORECTAL ADENOMA; COLORECTAL CANCER; COLORECTAL TUMOR; EPIGENETICS; GENE TARGETING; HUMAN; LUNG CANCER; NUTRITIONAL STATUS; PROSTATE CANCER; REVIEW; RISK REDUCTION; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU;

EID: 82455219031     PISSN: 15216918     EISSN: 15321916     Source Type: Journal    
DOI: 10.1016/j.bpg.2011.10.012     Document Type: Article

References (108)

1. A.C. Society The history of cancer 2011 [cited; 5/9/2011]:Available from: http://www.cancer.org/Cancer/CancerBasics/TheHistoryofCancer/the-history-of- cancer-what-is-cancer [Review]
2. B. Vogelstein Genetic alterations during colorectal-tumor development N Engl J Med 319 9 1988 525 532
3. D. Hanahan, and R.A. Weinberg The hallmarks of cancer Cell 100 2000 57 70 (Pubitemid 30046295)
4. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 5 2011 646 674
5. D.P. Slaughter, H.W. Southwick, and W. Smejkal Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin Cancer 6 5 1953 963 968
6. C.W. Boone Properties of intraepithelial neoplasia relevant to the development of cancer chemopreventive agents J Cell Biochem Suppl 28-29 1997 1 20 (Pubitemid 28246625)
7. C.P. Wen Minimum amount of physical activity for reduced mortality and extended life expectancy: a prospective cohort study Lancet 378 9798 2011 1244 1253
8. A. Balmain Molecular analysis of chemical carcinogenesis in the skin Br J Cancer Suppl 9 1988 72 75 (Pubitemid 19054744)
9. S.H. Yuspa Multistage carcinogenesis in the skin J Investig Dermatol Symp Proc 1 2 1996 147 150 (Pubitemid 126759358)
10. G.J. Kelloff Approaches to the development and marketing approval of drugs that prevent cancer Cancer Epidemiol Biomarkers Prev 4 1 1995 1 10
11. M.B. Sporn Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids) Fed Proc 35 1976 1332 1338
12. M.H. Gail Projecting individualized probabilities of developing breast cancer for white females who are being examined annually J Natl Cancer Inst 81 24 1989 1879 1886 (Pubitemid 20026073)
13. P.B. Bach Variations in lung cancer risk among smokers J Natl Cancer Inst 95 6 2003 470 478 (Pubitemid 36432421)
14. M.R. Spitz A risk model for prediction of lung cancer J Natl Cancer Inst 99 9 2007 715 726 (Pubitemid 47073532)
15. F.M. Giardiello Sulindac and polyp regression Cancer Metastasis Rev 13 3-4 1994 279 283
16. P.H. Gann Low-dose aspirin and incidence of colorectal tumors in a randomized trial J Natl Cancer Inst 85 15 1993 1220 1224 (Pubitemid 23223527)
17. B. Fisher Tamoxifen for prevention of breast cancer: report of the National surgical adjuvant breast and bowel project P-1 study J Natl Cancer Inst 90 18 1998 1371 1388 (Pubitemid 28439961)
18. J.R. Johnson Accelerated approval of oncology products: the food and drug administration experience J Natl Cancer Inst 103 8 2011 636 644
19. J.A. O'Shaughnessy Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development Clin Cancer Res 8 2 2002 314 346
20. G. Steinbach The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis N Engl J Med 342 26 2000 1946 1952 (Pubitemid 30419089)
21. G.S. Omenn Risk factors for lung cancer and for intervention effects in CARET, the beta-carotene and retinol efficacy trial J Natl Cancer Inst 88 1996 1550 1559 (Pubitemid 26374508)
22. P. Greenwald Chemoprevention of cancer Sci Am 275 3 1996 96 99
23. G.E. Goodman The beta-carotene and retinol efficacy trial: incidence of lung cancer and cardiovascular disease mortality during 6-year follow-up after stopping beta-carotene and retinol supplements J Natl Cancer Inst 96 23 2004 1743 1750 (Pubitemid 39654568)
24. Alpha-Tocopherol, beta carotene cancer prevention study group N Engl J Med 330 1994 1029 1035
25. J.A. Baron Folate intake, alcohol consumption, cigarette smoking, and risk of colorectal adenomas J Natl Cancer Inst 90 1 1998 57 62 (Pubitemid 28078082)
26. W.N. William Molecular targets for cancer chemoprevention Nat Rev Drug Discov 8 2009 213 225
27. V.E. Steele Preclinical drug development paradigms for chemopreventives Hematol Oncol Clin North Am 12 5 1998 943 961 v-vi (Pubitemid 28476034)
28. G.J. Kelloff, V.E. Steele, and C.C. Sigman R.E. Harris, Chemoprevention of cancer by NSAIDs and selective COX-2 blockade. COX-2 blockade in cancer prevention and therapy 2002 Humana Press, Inc Totowa
29. S.H. Yuspa, and M.C. Poirier Chemical carcinogenesis: from animal models to molecular models in one decade Adv Cancer Res 50 1988 25 70
30. E.T. Hawk Can animal models help us select specific compounds for cancer prevention trials? Recent Results Cancer Res 166 2005 71 87
31. I. Erdelyi Western-style diets induce oxidative stress and dysregulate immune responses in the colon in a mouse model of sporadic colon cancer J Nutr 139 11 2009 2072 2078
32. V.G. Vogel Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial JAMA 295 23 2006 2727 2741
33. D.L. Lamm Efficacy and safety of bacille Calmette-Guerin immunotherapy in superficial bladder cancer Clin Infect Dis 31 Suppl. 3 2000 S86 S90
34. J.A. Baron Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial Lancet 372 9651 2008 1756 1764
35. S.D. Solomon Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis Circulation 117 16 2008 2104 2113 (Pubitemid 351572169)
36. L. Zhang Chemoprevention of colorectal cancer by targeting APC-deficient cells for apoptosis Nature 464 7291 2010 1058 1061
37. C.J. Hawkey Esomeprazole for the management of upper gastrointestinal symptoms in patients who require NSAIDs: a review of the NASA and SPACE double-blind, placebo-controlled studies Clin Drug Investig 29 10 2009 677 687
38. J.M. Scheiman, and C.E. Hindley Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events Clin Ther 32 4 2010 667 677
39. J.A. Jankowski, and P.A. Hooper Chemoprevention in Barrett's esophagus: a pill a day? Gastrointest Endosc Clin N Am 21 1 2010 155 170
40. F.L. Meyskens Jr. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial Cancer Prev Res (Phila) 1 1 2008 32 38
41. A.E. Lathrop, and L. Loeb Further investigations on the origin of tumors in mice. III. On the part played by internal secretion in the spontaneous development of tumors J Cancer Res 1 1 1916 1 19
42. G.T. Beatson On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrated cases Lancet 2 1896 p. 104-107 and 162-165
43. R. Peto Can dietary beta-carotene materially reduce human cancer rates? Nature 290 5803 1981 201 208
44. R.G. Ziegler A review of epidemiologic evidence that carotenoids reduce the risk of cancer J Nutr 119 1 1989 116 122 (Pubitemid 19059544)
45. R.B. Shekelle Dietary vitamin A and risk of cancer in the western electric study Lancet 2 8257 1981 1185 1190
46. E. Bjelke Dietary vitamin A and human lung cancer Int J Cancer 15 1975 561 565
47. G. Kvale, E. Bjelke, and J.J. Gart Dietary habits and lung cancer risk Int J Cancer 31 4 1983 397 405 (Pubitemid 13121285)
48. The alpha-tocopherol, beta-carotene lung cancer prevention study: design, methods, participant characteristics, and compliance. The ATBC Cancer Prevention Study Group Ann Epidemiol 4 1 1994 1 10
49. G.S. Omenn Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease N Engl J Med 334 18 1996 1150 1155 (Pubitemid 26137973)
50. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The alpha-tocopherol, beta carotene cancer prevention study group N Engl J Med 330 1994 1029 1035
51. O.P. Heinonen Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial J Natl Cancer Inst 90 6 1998 440 446 (Pubitemid 28160635)
52. L.C. Clark Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial Br J Urol 81 5 1998 730 734 (Pubitemid 28316638)
53. A.J. Duffield-Lillico Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the nutritional prevention of cancer trial BJU Int 91 7 2003 608 612 (Pubitemid 36583728)
54. W.J. Blot Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population J Natl Cancer Inst 85 18 1993 1483 1492 (Pubitemid 23269183)
55. E.A. Klein SELECT: the selenium and vitamin E cancer prevention trial Urol Oncol 21 1 2003 59 65 (Pubitemid 41121900)
56. S.M. Lippman Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the selenium and vitamin E cancer prevention trial (SELECT) JAMA 301 1 2009 39 51
57. E.A. Klein Vitamin E and the risk of prostate cancer: the selenium and vitamin E cancer prevention trial (SELECT) JAMA 306 14 2011 1549 1556
58. A.R. Kristal, and S.M. Lippman Nutritional prevention of cancer: new directions for an increasingly complex challenge J Natl Cancer Inst 101 6 2009 363 365
59. J.L. Viner, E. Hawk, and S.M. Lippman Cancer chemoprevention D. Schottenfeld, J.R. Fraumeni, Cancer epidemiology and prevention 2006 Oxford University Press Oxford 1318 1340
60. V.C. Jordan Anti-oestrogen action in experimental breast cancer Recent Results Cancer Res 71 1980 30 44 (Pubitemid 10121381)
61. B. Fisher Tamoxifen for the prevention of breast cancer: current status of the National surgical adjuvant breast and bowel project P-1 study J Natl Cancer Inst 97 2005 1652 1662 (Pubitemid 41672231)
62. K.A. Metcalfe The use of preventive measures among healthy women who carry a BRCA1 or BRCA2 mutation Fam Cancer 4 2 2005 97 103 (Pubitemid 40897809)
63. P.E. Goss Exemestane for breast-cancer prevention in postmenopausal women N Engl J Med 364 25 2011 2381 2391
64. M.H. Chang Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group N Engl J Med 336 26 1997 1855 1859
65. L.A. Koutsky A controlled trial of a human papillomavirus type 16 vaccine N Engl J Med 347 21 2002 1645 1651 (Pubitemid 35340782)
66. E. Hawk, and J.L. Viner The critical role of risk-benefit assessments in cancer prevention Cancer Epidemiol Biomarkers Prev 14 2 2005 297 298 (Pubitemid 40270088)
67. J.A. Baron Calcium supplements for the prevention of colorectal adenomas. Calcium polyp prevention study group N Engl J Med 340 2 1999 101 107 (Pubitemid 29054844)
68. M.V. Grau Prolonged effect of calcium supplementation on risk of colorectal adenomas in a randomized trial J Natl Cancer Inst 99 2 2007 129 136
69. FDA Health claims: calcium, vitamin D, and osteoporosis 2008 cited; Available from http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid= b39601aa6d95670faf7f0c388a191312&rgn=div8&view=text&node=21:2.0.1.1. 2.5.1.3&idno=21
70. I.M. Thompson The influence of finasteride on the development of prostate cancer N Engl J Med 349 3 2003 215 224 (Pubitemid 36859473)
71. M.W. Redman Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach Cancer Prev Res. (Phila) 1 2008 174 181
72. G.L. Andriole Effect of dutasteride on the risk of prostate cancer N Engl J Med 362 2010 1192 1202
73. M.R. Theoret The risks and benefits of 5alpha-reductase inhibitors for prostate-cancer prevention N Engl J Med 365 2 2011 97 99
74. J.R. Vane, and R.M. Botting Mechanism of action of antiinflammatory drugs Int J Tissue React 20 1 1998 3 15 (Pubitemid 29077601)
75. A. Greenhough The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment Carcinogenesis 30 3 2009 377 386
76. R.E. Harris Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung Inflammopharmacology 17 2 2009 55 67
77. P.M. Rothwell Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials Lancet 376 2010 1741 1750
78. J.A. Baron A randomized trial of aspirin to prevent colorectal adenomas N Engl J Med 348 10 2003 891 899 (Pubitemid 36297997)
79. R. Benamouzig Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial Gastroenterology 125 2 2003 328 336 (Pubitemid 36929412)
80. R.S. Sandler A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer N Engl J Med 348 10 2003 883 890 (Pubitemid 36297996)
81. J. Cuzick Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement Lancet Oncol 10 5 2009 501 507
82. N.R. Cook Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial JAMA 294 1 2005 47 55 (Pubitemid 41002838)
83. D.A. Corley Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis Gastroenterology 124 1 2003 47 56 (Pubitemid 36055338)
84. P.F. Coogan NSAIDs and risk of colorectal cancer according to presence or absence of family history of the disease Cancer Causes Control 11 3 2000 249 255 (Pubitemid 30182142)
85. A.T. Chan Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer JAMA 294 8 2005 914 923 (Pubitemid 41215460)
86. E. Flossmann, and P.M. Rothwell Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies Lancet 369 9573 2007 1603 1613 (Pubitemid 46710123)
87. F.L. Lanza, F.K. Chan, and E.M. Quigley Guidelines for prevention of NSAID-related ulcer complications Am J Gastroenterol 104 3 2009 728 738
88. V.L. Serebruany Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials Am J Cardiol 95 10 2005 1218 1222 (Pubitemid 40616424)
89. C. Patrono Antiplatelet drugs: American college of chest physicians evidence-based clinical practice guidelines (8th Edition) Chest 133 6 Suppl. 2008 199S 233S (Pubitemid 351894914)
90. K. Cooper Chemoprevention of colorectal cancer: systematic review and economic evaluation Health Technol Assess 14 32 2010 1 206
91. H. Squires Cost-effectiveness of aspirin, celecoxib, and calcium chemoprevention for colorectal cancer Clin Ther 33 9 2011 1289 1305
92. C. Bombardier Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group N Engl J Med 343 21 2000 1520 1528 2 p. following 1528
93. F.E. Silverstein Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib long-term arthritis safety study JAMA 284 10 2000 1247 1255
94. R.K. Phillips A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis Gut 50 6 2002 857 860 (Pubitemid 34539050)
95. K. Huang Clinical characteristics and outcomes in familial adenomatous polyposis patients with a long-term treatment of celecoxib: a matched cohort study Fam Cancer 10 2 2011 303 308
96. P.M. Lynch The safety and efficacy of celecoxib in children with familial adenomatous polyposis Am J Gastroenterol 105 6 2010 1437 1443
97. M.M. Bertagnolli Celecoxib for the prevention of sporadic colorectal adenomas N Engl J Med 355 9 2006 873 884 (Pubitemid 44315980)
98. N. Arber Celecoxib for the prevention of colorectal adenomatous polyps N Engl J Med 355 9 2006 885 895 (Pubitemid 44315981)
99. S.D. Solomon Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention N Engl J Med 352 11 2005 1071 1080 (Pubitemid 40365348)
100. M.M. Bertagnolli Five-year efficacy and safety analysis of the adenoma prevention with celecoxib trial Cancer Prev Res (Phila) 2 4 2009 310 321
101. Wu X, Lippman SM. An intermittent approach for cancer chemoprevention. Nat Rev Cancer, in press.
102. T. Dobzhansky Genetics of natural populations. XIII. Recombination and variability in populations of Drosophila melanogaster Genetics 31 3 1946 269 290
103. L. Guarente Synthetic enhancement in gene interaction: a genetic tool come of age Trends Genet 9 10 1993 362 366 (Pubitemid 23296291)
104. J.C. Lucchesi Synthetic lethality and semi-lethality among functionally related mutants of Drosophila melanogaster Genetics 59 1 1968 37 44
105. W.G. Kaelin Jr. The concept of synthetic lethality in the context of anticancer therapy Nat Rev Cancer 5 9 2005 689 698 (Pubitemid 41486362)
106. H.C. Reinhardt Exploiting synthetic lethal interactions for targeted cancer therapy Cell Cycle 8 19 2009 3112 3119
107. S. Huang Lung-cancer chemoprevention by induction of synthetic lethality in mutant KRAS premalignant cells in vitro and in vivo Cancer Prev Res (Phila) 4 5 2011 666 673
108. M. Barthelman Inhibitory effects of perillyl alcohol on UVB-induced murine skin cancer and AP-1 transactivation Cancer Res 58 4 1998 711 716 (Pubitemid 28099482)